



Name	Ju Dong Yang, MD
Affiliation	Cedars Sinai Medical Center
Country	USA
Major Field	Liver cancer

Educational Background

03/1999 - 02/2005 Medical School - Sungkyunkwan University School of Medicine, Seoul, Korea

03/2009 - 05/2011 Research Fellowship - Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

09/2009 - 05/2011 Master's degree in clinical and translational research - Clinical and Translational Science Activities, Mayo Graduate School

06/2011 - 05/2014 Residency - Internal Medicine, University of Arkansas For Medical Science, Little Rock, AR

07/2014 - 12/2017 Gastroenterology Fellowship, T32 Grant - Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

01/2018 - 12/2018 Transplant Hepatology Fellowship - Transplant Hepatology, Mayo Clinic, Rochester, MN

Professional Experience

7/1/2023 - present Associate Professor of Medicine, Department of Medicine, Cedars-Sinai

1/2019 - present Medical Director, Liver Cancer Program, Karsh Division of Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, CA

7/2023 - present Health Sciences Associate Clinical Professor, David Geffen School of Medicine, University of California Los Angeles

Main Scientific Publications

1) Risk stratification and early detection biomarkers for precision HCC screening. Lee YT, Fujiwara N, Yang JD, Hoshida Y. Hepatology. 2022 Sep 9;10.1002/hep.32779.

2) Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States. Lee YT, Singal AG, Lauzon M, Agopian VG, Luu M, Nouredin M, Todo T, Kim IK, Friedman ML, Kosari K, Nissen NN, Roberts LR, Heimbach JK, Gores GJ, Yang JD. Cancer. 2022 Oct;128(20):3610-3619.

3) HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen



M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Nouredin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. *Hepatology*. 2023 Mar 1;77(3):774-788.

4) Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Ahn JC, Lauzon M, Luu M, Nouredin M, Ayoub W, Kuo A, Sundaram V, Kosari K, Nissen N, Gong J, Hendifar A, Roberts LR, Abou-Alfa GK, Singal AG, Yang JD. *Hepatology*. 2022 Apr 16.

5) Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. Karim MA, Singal AG, Kum HC, Lee YT, Park S, Rich NE, Nouredin M, Yang JD. *Clin Gastroenterol Hepatol*. 2022 Mar 17

6) Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. Govalan R, Luu M, Lauzon M, Kosari K, Ahn JC, Rich NE, Nissen N, Roberts LR, Singal AG, Yang JD. *Hepatol Commun*. 2022 Jan;6(1):223-236.

7) The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Lee YT, Wang JJ, Luu M, Nouredin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. *J Natl Cancer Inst*. 2021 Nov 2;113(11):1531-1541.